> Accueil / Recherche


Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 associated lymphoproliferative disorders. Oksenhendler E, Boutboul D, Galicier L. Blood. 2019 Jan 4.

A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. Baker TS, Gambino KJ, Schriefer L, Lim JY, Steinberg KM, Fajgenbaum DC, Martín García-Sancho A, Byun M. Blood Adv. 2018 Nov 13;2(21):2959-2963.

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Fajgenbaum DC. Blood. 2018 Nov 29;132(22):2323-2330.

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC. Br J Haematol. 2018 Sep 11.

ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, Hershfield M, Liston A, Wouters C. Pediatrics. 2018 Sep;142(3). 2017-2266.

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S, Ohgami RS. Blood Adv. 2018 Mar 13;2(5):481-491.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. Blood. 2018 Nov 15;132(20):2115-2124. Epub 2018 Sep 4. Review.

The full spectrum of Castleman disease: 273 patients studied over 20 years. Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gérard L, Galicier L. Br J Haematol. 2018 Jan;180(2):206-216

Clinical and molecular characteristics of unicentric mediastinal Castleman disease. Legras A, Tallet A, Didelot A, Cazes A, Danel C, Hin A, Borie R, Crestani B, Castier Y, Bagan P, Le Pimpec-Barthes F, Riquet M, Blons H, Mordant P. J Thorac Dis. 2018 Apr;10(4):2079-2088. 

Multicentric Castleman disease: Where are we now? Wang HW, Pittaluga S, Jaffe ES. Semin Diagn Pathol. 2016 May 16
Idiopathic multicentric Castleman's disease: a systematic literature review. Liu AY, Nabel CS, Finkelman BS, et al. Lancet Haematol. 2016 Apr;3(4):e163-75.
Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease. Musters A, Assaf A, Gerlag DM, Tak PP, Tas SW. Front Immunol. 2015 Dec 11;6:625.
Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Munshi N1, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Leuk Lymphoma. 2015 May;56(5):1252-60.
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. van Rhee F, Casper C, Voorhees PM, et al. Oncotarget. 2015 Oct 6;6(30):30408-19
Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Dong Y, Wang M, Nong L, et al. Br J Haematol. 2015 Jun;169(6):834-42.
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Fajgenbaum DC, van Rhee F, Nabel CS. Blood. 2014 May 8;123(19):2924-33.
The use of monoclonal antibodies to treat Castleman's disease. Robey RC, Mletzko S, Colley C, Balachandran K, Bower M. Immunotherapy. 2014;6(2):211-9.
Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). Kawabata H, Takai K, Kojima M, et al. J Clin Exp Hematop. 2013;53(1):57-61.
Surgery in Castleman's disease: a systematic review of 404 published cases. Talat N, Belgaumkar AP, Schulte KM. Ann Surg. 2012 Apr;255(4):677-84
Castleman's disease: systematic analysis of 416 patients from the literature. Talat N, Schulte KM. Oncologist. 2011;16(9):1316-24.
The spectrum of Castleman's disease: mimics, radiologic pathologic correlation and role of imaging in patient management. Madan R, Chen JH, Trotman-Dickenson B, Jacobson F, Hunsaker A. Eur J Radiol. 2012 Jan;81(1):123-31.
Castleman disease. Dispenzieri A. Cancer Treat Res. 2008;142:293-330.
The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Casper C.  Br J Haematol. 2005 Apr;129(1):3-17
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Nishimoto N, Kanakura Y, Aozasa K, et al. Blood. 2005 Oct 15;106(8):2627-32.

Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. Wong SW, Bergquam EP, Swanson RM, et al. J Exp Med. 1999;190(6):827-40.

Paediatric Castleman disease: report of seven cases and review of the literature. Parez N, Bader-Meunier B, Roy CC, Dommergues JP. Eur J Pediatr. 1999 Aug;158(8):631-7.
Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Am J Clin Pathol. 1994 Mar;101(3):290-5
Multicentric Castleman's disease. Peterson BA, Frizzera G. Semin Oncol. 1993 Dec;20(6):636-47

Angiofollicular lymphoid hyperplasia (Castleman's disease) in two mice treated with polyoma virus or urethane. Williams AO, Banks PM, Liebelt AG, Stewart HL, Saffiotti U. Toxicol Pathol. 1993;21(1):26-34.

Localized mediastinal lymph node hyperplasia resembling thymoma. Castleman B, Iverson L, Menendez VP. Cancer. 1956 Jul-Aug;9(4):822-30.

CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. N Engl J Med. 1954 Jan 7;250(1):26-30.